Drug Type Small molecule drug |
Synonyms TFX05 01, TFX05-01, TFX0501 |
Target |
Action inhibitors |
Mechanism 17β-HSD5 inhibitors(Aldo-keto-reductase family 1 member C3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | China | 05 Jun 2022 | |
Adrenocortical Carcinoma | IND Approval | China | 17 Jun 2025 | |
Hematologic Neoplasms | IND Approval | China | 14 Jul 2023 |